Table 3 Summary of adverse event during the treatment period (n = 30)
Patients with adverse event | Number (%) |
|---|---|
Any adverse event | 14(46.7) |
Serious adverse event | 4(13.3) |
 Renal dysfunction | 2(6.7) |
 Hepatic decompensation | 1(3.3) |
 Upper respiratory tract infection | 1(3.3) |
Discontinuation due to adverse event | 3(10) |
Death | 0(0) |
Common adverse event | |
 Anemia | 6(20) |
 Nausea | 3(10) |
 Fatigue | 2(6.7) |
 Palpitation | 2(6.7) |
 Pruritus/rash | 2(6.7) |
 Dizziness/headache | 2(6.7) |
 Shortness of breath | 1(3.3) |
 Sleep disorders | 1(3.3) |